DENOVO BIOPHARMA LLC
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2011-01-01
- Employees
- 11
- Market Cap
- -
A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant Depression
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 197
- Registration Number
- NCT05113771
- Locations
- 🇺🇸
University of Alabama at Birmingham, Huntsville, Alabama, United States
🇺🇸Collaborative Neuroschience Research, LLC, Garden Grove, California, United States
🇺🇸Behavioral Research Specialists, LLC, Glendale, California, United States
A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
- Conditions
- Interventions
- First Posted Date
- 2018-12-14
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 260
- Registration Number
- NCT03776071
- Locations
- 🇺🇸
New York University Medical Oncology Associates, New York, New York, United States
🇺🇸University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States
🇺🇸Messino Cancer Centers, Asheville, North Carolina, United States
Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™
- Conditions
- Interventions
- First Posted Date
- 2017-08-28
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 256
- Registration Number
- NCT03263026
- Locations
- 🇺🇸
Mercy Research, Springfield, Missouri, United States
🇺🇸University of Texas Southwestern Medical Center - Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas, United States
🇺🇸Seattle Cancer Center Alliance, Seattle, Washington, United States
A Study of LY2140023 in Healthy Participants
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- Denovo Biopharma LLC
- Registration Number
- NCT01659177
- Locations
- 🇨🇭
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Allschwil, Switzerland
A Study of LY2140023 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2012-07-11
- Last Posted Date
- 2021-09-21
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 18
- Registration Number
- NCT01637142
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom
A Study of LY2140023 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2012-05-31
- Last Posted Date
- 2021-09-21
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 27
- Registration Number
- NCT01609218
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom
A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2012-05-25
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 86
- Registration Number
- NCT01606436
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas, United States
A Study of LY2140023 in Healthy Males and Females
- Conditions
- Interventions
- First Posted Date
- 2012-05-04
- Last Posted Date
- 2021-09-21
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 35
- Registration Number
- NCT01591330
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom
A Study of LY2140023 in Hepatically-Impaired Participants
- First Posted Date
- 2011-11-21
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 37
- Registration Number
- NCT01475136
- Locations
- 🇭🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Balatonfüred, Hungary
A Physical Dependence Study in Schizophrenia
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2022-09-14
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 123
- Registration Number
- NCT01452919
- Locations
- 🇬🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tripoli, Greece